Post-earnings recap
Reported
Tue, Apr 28, 2026
EPS actual
$0.27
EPS est.
$0.18
EPS surprise
+50.00%
1-day move
+23.48%
Kiniksa Pharmaceuticals reported a strong EPS that exceeded expectations, leading to a 1.92% increase in stock price. The positive surprise in EPS indicates effective cost management or better-than-expected sales. However, the lack of revenue data and guidance leaves some uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.27 | $0.16 | +50.00% |
| Revenue | N/A | $206M | N/A |
Management expressed cautious optimism about the company's performance. They noted the strong EPS results but did not provide specific guidance for future quarters.
Management highlighted the strong performance in EPS as a positive indicator.
They emphasized ongoing efforts to enhance product development.
There was a focus on future opportunities despite not providing specific guidance.
Kiniksa Pharmaceuticals International, plc (KNSA) operates in the biotechnology sector, focusing on developing innovative therapies for patients with serious diseases. With a market cap of $3 billion, the company plays a significant role in the healthcare landscape, particularly in addressing unmet medical needs.
Last quarter
In Q4-2025, Kiniksa reported an EPS of $0.17, which was significantly below the expected $0.29, leading to an 8.21% drop in stock price the following day. The company continues to navigate challenges in meeting market expectations.
EPS beat streak
0Q
EPS beat rate
38%
Avg EPS surprise
-115.26%
Avg 1-day reaction
+6.88%
Analysts expect Kiniksa to report an EPS of $0.16 and revenue of $206 million for Q1-2026. The market is closely watching how the company addresses previous earnings misses.
Bull case
If Kiniksa can exceed the EPS estimate and show strong revenue growth, it may signal a turnaround in performance, boosting investor confidence.
Bear case
Conversely, if the company misses expectations again, it could raise concerns about its ability to execute its business strategy, leading to further stock declines.
Key metrics to watch
Earnings Per Share (EPS)
$0.16EPS is a key indicator of the company's profitability and financial health, and it helps investors gauge performance against expectations.
Revenue
$206MRevenue figures provide insight into the company's sales performance and market demand for its products, which is crucial for growth.
The print will turn on these.
Q1
Will Kiniksa's EPS exceed $0.16, and how will management address past earnings misses?
A positive EPS surprise could restore investor confidence, while another miss could lead to further skepticism about the company's strategy.
Q2
What specific revenue figures will Kiniksa report, and how do they align with the $206 million consensus?
Revenue performance is critical for assessing the company's growth trajectory and market demand for its products.
—
Est. EPS
$1.52
Est. Rev
$3.6B
Impl. Move
±39.2%
Why consensus could be wrong
The Street may be underestimating Kiniksa's potential for a strong recovery given recent product developments that have not been fully reflected in analyst models.
Supporting evidence
Kiniksa's recent product pipeline updates suggest potential for higher revenue than currently anticipated.
The significant implied move in options indicates that traders are expecting a more volatile response than historical averages would suggest.
Key risk
If Kiniksa's revenue comes in significantly above $210 million, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is debating whether Kiniksa can turn around its recent performance after a series of earnings misses.
Bull confirmed if
An EPS of $0.20 or higher, coupled with revenue exceeding $210 million, would confirm a strong recovery.
Bear confirmed if
An EPS below $0.13 or revenue below $201 million would indicate ongoing challenges.
What the market is pricing for the move.
Implied Move
±37.04%
Historical Avg
±13.6%
The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±16.1% while KNSA has averaged ±13.6% over the last 8 prints — setup is pricing rich.
ATM IV
0.8%
30d HV
34.3%
Smart-money positioning from the most recent 13F filings.
Institutional
101.02%
of float
Insider
3.51%
of float
Holders
384
institutions
Top Holders· as of Jun 2026
FMR, LLC
6,971,361 sh · $543.5M
17.30%
2.2%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Kiniksa beats expectations, history suggests the stock could rise by an average of 18.59%, confirming a positive turnaround narrative.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
A miss could lead to a decline of around 4.58%, reinforcing concerns about the company's ability to meet market expectations.
The lines on the call that would change the story.
Rubric Capital Management LP
3,999,800 sh · $311.8M
9.92%
6.7%
Baker Bros. Advisors, LP
2,834,643 sh · $221.0M
7.03%
0.3%
Blackrock Inc.
2,739,615 sh · $213.6M
6.80%
462.8%
Tang Capital Management, LLC
2,259,889 sh · $176.2M
5.61%
Flat
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.